Gaya Herald

Bipolar Disorder Market, Epidemiology and Market Forecast -2030

 Breaking News
  • No posts were found

Bipolar Disorder Market, Epidemiology and Market Forecast -2030

June 25
01:55 2021
Bipolar Disorder Market, Epidemiology and Market Forecast -2030

DelveInsight Business Research LLP
DelveInsight’s ‘Bipolar Disorder Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the Bipolar Disorder (Manic Depression), historical and forecasted epidemiology as well as the Bipolar Disorder (Manic Depression) market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Bipolar Disorder Manic Depression Market

The Bipolar Disorder (Manic Depression) market report provides current treatment practices, emerging drugs, Bipolar Disorder (Manic Depression) market share of the individual therapies, current and forecasted Bipolar Disorder (Manic Depression) market size from 2017 to 2030 segmented by seven major markets. The Report also covers current Bipolar Disorder (Manic Depression) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Bipolar Disorder (Manic Depression) Overview

Bipolar disorder (BD), previously known as manic depressive illness or manic depression, is a mental disorder characterized by wide mood swings from high (manic) to low (depressed). In manic episodes, a person can be delighted, irritable, and there is a marked increase in activity level, whereas, in depressive episodes, someone might feel sad, indifferent, or hopeless, in combination with a deficient activity level. Hypomanic episodes are also seen in patients, and it is a less severe form of mania. It is divided mainly into four subtypes BD-I, BD-II, cyclothymic disorder, and BD not otherwise specified (BD-NOS); the classification is based on the characteristics of mood swings.

Bipolar Disorder (Manic Depression) Epidemiology

The Bipolar Disorder (Manic Depression) epidemiology division provides insights about the historical and current Bipolar Disorder (Manic Depression) patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

  • In the year 2020, the total diagnosed prevalent case of Bipolar Disorder (Manic Depression) was 3,552,076 cases in the 7MM which are expected to grow during the study period, i.e., 2017–2030.
  • The disease epidemiology covered in the report provides historical as well as forecasted Bipolar Disorder (Manic Depression) epidemiology [segmented as Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression), Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression), Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression), and Total Treated Cases of Bipolar Disorder (Manic Depression)] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Bipolar Disorder Emerging Drugs

Lumateperone/ITI-007 (Intra-Cellular Therapies)

Lumateperone (ITI-007) is an investigational, first-in-class small molecule that provides selective and simultaneous modulation of serotonin, dopamine, and glutamate, three neurotransmitter pathways implicated in severe mental illness. It is a potent serotonin 5-HT2A receptor antagonist, a dopamine receptor phosphoprotein modulator (DPPM) acting as a presynaptic partial agonist and postsynaptic antagonist at dopamine D2 receptors, a dopamine D1 receptor-dependent indirect modulator of glutamate (both NDMA and AMPA), and a serotonin reuptake inhibitor. Currently, lumateperone is in Phase III clinical development as a novel treatment for Bipolar Disorder (Manic Depression). Lumateperone Bipolar Disorder (Manic Depression) clinical program consists of three monotherapy studies and one adjunctive study. The company submitted the sNDA to the US FDA in February 2021, and if approved, this drug would be the first therapy indicated for the treatment of depressive episodes associated with bipolar I or II disorder both as monotherapy and as adjunctive therapy in adults

NRX-100/NRX-101 (NeuroRx)

NeuroRx is developing a sequential therapy consisting of intravenous NRX-100 (ketamine HCL) for rapid stabilization of symptoms of depression and suicidal ideation followed by oral NRX-101 (fixed-dose combination of D-cycloserine and lurasidone) for maintenance of stabilization from symptoms of depression and suicidal ideation. NRX-101 is a proprietary, oral fixed-dose combination of two FDA-approved drugs: D-cycloserine, an NMDA receptor modulator; and Lurasidone (Latuda), a 5-HT2a receptor antagonist. NRX-101’s proprietary dual-mechanism of action targets the NMDA and 5-HT2a receptors – two key receptors in the brain. Currently, the molecule is under investigation in Phase III clinical trial for rapid stabilization of acute suicidal ideation and behavior in patients with Bipolar Disorder (Manic Depression). Additionally, the company is also initiating a Phase IIb/III clinical trial of NRX-100/NRX-101 to treat Bipolar Disorder (Manic Depression) in patients with ASIB. In September 2017, the US FDA granted fast track designation to NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone) for Bipolar Disorder (Manic Depression) with suicidal ideation.

SEP-4199 (Sunovion/Sumitomo Dainippon Pharma)

SEP-4199 is a nonracemic ratio of amisulpride enantiomers with the potential to be the first benzamide treatment available in the US for mood disorders. Sunovion discovered that the pharmacology of amisulpride is enantiomer-specific and that increasing the ratio of R-amisulpride to S-amisulpride increases the potency for serotonin 5-HT7 receptors relative to dopamine D2 receptors. SEP-4199 was designed to increase levels of serotonin 5-HT7 activity intended to enhance antidepressant efficacy and produce reduced levels of D2 receptor occupancy appropriate for the treatment of Bipolar Disorder (Manic Depression). The pharmacological effect of SEP-4199 is distinct from racemic amisulpride, which is approved in several countries outside the US for the treatment of schizophrenia and other psychiatric condition.

Brexpiprazole (Lundbeck/Otsuka Pharmaceutical)

Brexpiprazole is a molecule discovered by Otsuka and co-developed by Otsuka and Lundbeck. Brexpiprazole is an atypical antipsychotic agent with a partial dopamine receptor D2 agonist effect. It is a partial agonist at dopamine D2 receptors designed to have a similar binding affinity to dopamine and serotonin receptors. The efficacy of brexpiprazole may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors. Brexpiprazole exhibits high affinity (subnanomolar) for these receptors as well as for noradrenaline alpha1B/2C receptors.

Bipolar Disorder Market Outlook

At present, some companies have initiated clinical trials that investigate new treatment options. Key players such as Intra-Cellular Therapies (Caplyta, also known as Lumateperone), NeuroRx (NRX-100/NRX-101), Sunovion (Sumitomo Dainippon Pharma) (SEP-4199), Lundbeck/Otsuka Pharmaceutical (Rexulti/Rxulti, also known as Brexpiprazole), COMPASS Pathways (COMP 360, also known as Psilocybin therapy), Celon Pharma (Falkieri), and several others are investigating their candidates for the management of Bipolar Disorder (Manic Depression) in the 7MM.

Key Findings

The Bipolar Disorder (Manic Depression) market size in the 7MM is expected to change during the study period 2017–2030. The therapeutic market of Bipolar Disorder (Manic Depression) in the seven major markets is expected to increase during the study period (2017–2030) with a CAGR of 11.9%. According to the estimates, the highest market size of Bipolar Disorder (Manic Depression) is found in the United States followed by Germany.

The United States Market Outlook

The total market size of Bipolar Disorder (Manic Depression) therapies in the United States is expected to increase with a CAGR of 11.6% in the study period (2017–2030).

 

EU-5 Countries: Market Outlook

The total market size of Bipolar Disorder (Manic Depression) therapies in EU-5 countries is expected to increase with a CAGR of 13.4% in the study period (2017–2030).

 

Japan Market Outlook

The total market size of Bipolar Disorder (Manic Depression) therapies in Japan is expected to increase with a CAGR of 11.5% in the study period (2017–2030).

Request for sample pages @ Bipolar Disorder Market

Table of contents

1. Key Insights

2. Report Introduction

3. Bipolar Disorder (Manic Depression) Market Overview at a Glance

3.1. Market Share (%) Distribution of Bipolar Disorder (Manic Depression) in 2017

3.2. Market Share (%) Distribution of Bipolar Disorder (Manic Depression) in 2030

4. Executive Summary of Bipolar Disorder (Manic Depression)

5. Epidemiology and Market Methodology

6. Disease Background and Overview

6.1. Introduction

6.2. Difference between Bipolar and Unipolar Depression

6.3. Classification of BD According to DSM-5

6.4. Signs and symptoms

6.5. Causes

6.6. Risk Factors

6.7. Pathophysiology

6.8. Genetic Findings in BD

6.9. Biomarkers

7. Diagnosis of Bipolar Disorder

7.1. Diagnostic criteria for major forms of BD

7.1.1. Diagnosis to rule out thyroid disorders

7.2. Differential Diagnosis

7.3. Diagnostic Guidelines

7.3.1. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology Guidelines

7.3.2. The National Institute for Health and Care Excellence (NICE) guidelines for the diagnosis of the bipolar disorder

8. Current Treatment Practices of Bipolar Disorder

8.1. Treatment of Bipolar Disorder

8.1.1. Treatment Algorithm

8.2. Treatment Guidelines

8.2.1. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute Bipolar Disorder (Manic Depression)

8.2.2. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of the bipolar disorder

8.2.3. The American Psychiatric Association Practice Guideline for the Treatment of Bipolar Disorder

8.2.4. The National Institute for Health and Care Excellence (NICE) guidelines for the treatment of the bipolar disorder

8.2.5. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology

8.2.6. Guideline for the treatment of bipolar disorder by the Japanese Society of Mood Disorders, 2012

8.2.7. International Society for Bipolar Disorders Clinical (ISBD) Recommendations for Antidepressant Use in Bipolar Disorders

8.2.8. The International College of Neuro-psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017)

8.3. Comparison of Bipolar disorder guidelines

9. Epidemiology and Patient Population

9.1. Key Findings

9.2. Epidemiology of Bipolar Disorder (Manic Depression)

9.3. Epidemiology Scenario: 7MM

9.3.1. Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

9.3.2. Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

9.3.3. Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

9.3.4. Total Treated Cases of Bipolar Disorder (Manic Depression)

10. The United States

10.1. Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

10.2. Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

10.3. Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

10.4. Total Treated Cases of Bipolar Disorder (Manic Depression)

11. EU-5

11.1. Germany

11.1.1. Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.1.2. Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.1.3. Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.1.4. Total Treated Cases of Bipolar Disorder (Manic Depression)

11.2. France

11.2.1. Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.2.2. Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.2.3. Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.2.4. Total Treated Cases of Bipolar Disorder (Manic Depression)

11.3. Italy

11.3.1. Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.3.2. Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.3.3. Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.3.4. Total Treated Cases of Bipolar Disorder (Manic Depression)

11.4. Spain

11.4.1. Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.4.2. Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.4.3. Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.4.4. Total Treated Cases of Bipolar Disorder (Manic Depression)

11.5. The United Kingdom

11.5.1. Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.5.2. Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.5.3. Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.5.4. Total Treated Cases of Bipolar Disorder (Manic Depression)

12. Japan

12.1. Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

12.2. Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

12.3. Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

12.4. Total Treated Cases of Bipolar Disorder (Manic Depression)

13. Patient Journey

14. Key Endpoints in Bipolar Disorder (Manic Depression) Clinical Trials

15. Marketed Therapies

15.1. Vraylar (Cariprazine): Allergan (AbbVie)/Gedeon Richter

15.1.1. Drug Description

15.1.2. Regulatory Milestones

15.1.3. Other Developmental Activities

15.1.4. Pivotal Clinical Trial

15.1.5. Ongoing Current Pipeline Activity

15.2. Latuda (Lurasidone Hydrochloride): Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma)

15.2.1. Drug Description

15.2.2. Regulatory Milestones

15.2.3. Other Developmental Activities

15.2.4. Pivotal Clinical Trial

16. Emerging Therapies

16.1. Caplyta (ITI-007; Lumateperone): Intra-Cellular Therapies

16.1.1. Product Description

16.1.2. Other Developmental Activities

16.1.3. Clinical Development

16.1.4. Safety and Efficacy

16.2. NRX-100/NRX-101: NeuroRx

16.2.1. Product Description

16.2.2. Other Developmental Activities

16.2.3. Clinical Development

16.2.4. Safety and Efficacy

16.3. SEP-4199: Sunovion (Sumitomo Dainippon Pharma)

16.3.1. Product Description

16.3.2. Other Developmental Activities

16.3.3. Clinical Development

16.3.4. Safety and Efficacy

16.4. Rexulti/Rxulti (Brexpiprazole): Lundbeck/Otsuka Pharmaceutical

16.4.1. Product Description

16.4.2. Other Developmental Activities

16.4.3. Clinical Development

16.4.4. Safety and Efficacy

16.5. Falkieri (Esketamine): Celon Pharma

16.5.1. Product Description

16.5.2. Other Developmental Activities

16.5.3. Clinical Development

16.5.4. Safety and Efficacy

16.6. COMP 360 (Psilocybin): COMPASS Pathways

16.6.1. Product Description

16.6.2. Other Developmental Activities

16.6.3. Clinical Development

17. Bipolar Disorder (Manic Depression): 7 Major Market Analysis

17.1. Key Findings

17.2. Market Outlook

17.3. 7MM Market Size

17.3.1. Total Market Size of Bipolar Disorder (Manic Depression) in the 7MM

17.3.2. Market Size of Bipolar Disorder (Manic Depression) by Therapies in the 7MM

18. The United States Market Size

18.1. Total Market Size of Bipolar Disorder (Manic Depression) in the United States

18.2. Market Size of Bipolar Disorder (Manic Depression) by Therapies in the United States

19. EU-5 Market Size

19.1. Germany

19.1.1. Total Market size of Bipolar Disorder (Manic Depression) in Germany

19.1.2. Market Size of Bipolar Disorder (Manic Depression) by Therapies in Germany

19.2. France

19.2.1. Total Market size of Bipolar Disorder (Manic Depression) in France

19.2.2. Market Size of Bipolar Disorder (Manic Depression) by Therapies in France

19.3. Italy

19.3.1. Total Market size of Bipolar Disorder (Manic Depression) in Italy

19.3.2. Market Size of Bipolar Disorder (Manic Depression) by Therapies in Italy

19.4. Spain

19.4.1. Total Market size of Bipolar Disorder (Manic Depression) in Spain

19.4.2. Market Size of Bipolar Disorder (Manic Depression) by Therapies in Spain

19.5. The United Kingdom

19.5.1. Total Market size of Bipolar Disorder (Manic Depression) in the United Kingdom

19.5.2. Market Size of Bipolar Disorder (Manic Depression) by Therapies in the United Kingdom

20. Japan

20.1. Total Market size of Bipolar Disorder (Manic Depression) in Japan

20.2. Market Size of Bipolar Disorder (Manic Depression) by Therapies in Japan

21. Market Access and Reimbursement

21.1. Key HTA decisions for Bipolar Disorder (Manic Depression)

21.2. Patient Access Programs

22. Market Drivers

23. Market Barriers

24. SWOT Analysis

25. Unmet Needs

26. Appendix

26.1. Bibliography

26.2. Report Methodology

27. DelveInsight Capabilities

28. Disclaimer

29. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/ghaziabadonline/gayaherald.com/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share